Search Results
You are looking at 1 - 2 of 2 items for
- Author: Frank L Schwartz x
- Refine by access: All content x
Department of Specialty Medicine, Appalachian Rural Health Institute, Edison Biotechnology Institute, Department of Biomedical Sciences, Biomedical Engineering Program, Interthyr Corporation, Diabetes Research Center
Department of Specialty Medicine, Appalachian Rural Health Institute, Edison Biotechnology Institute, Department of Biomedical Sciences, Biomedical Engineering Program, Interthyr Corporation, Diabetes Research Center
Search for other papers by Kelly D McCall in
Google Scholar
PubMed
Search for other papers by Dawn Holliday in
Google Scholar
PubMed
Department of Specialty Medicine, Appalachian Rural Health Institute, Edison Biotechnology Institute, Department of Biomedical Sciences, Biomedical Engineering Program, Interthyr Corporation, Diabetes Research Center
Department of Specialty Medicine, Appalachian Rural Health Institute, Edison Biotechnology Institute, Department of Biomedical Sciences, Biomedical Engineering Program, Interthyr Corporation, Diabetes Research Center
Search for other papers by Eric Dickerson in
Google Scholar
PubMed
Search for other papers by Brian Wallace in
Google Scholar
PubMed
Department of Specialty Medicine, Appalachian Rural Health Institute, Edison Biotechnology Institute, Department of Biomedical Sciences, Biomedical Engineering Program, Interthyr Corporation, Diabetes Research Center
Search for other papers by Anthony L Schwartz in
Google Scholar
PubMed
Department of Specialty Medicine, Appalachian Rural Health Institute, Edison Biotechnology Institute, Department of Biomedical Sciences, Biomedical Engineering Program, Interthyr Corporation, Diabetes Research Center
Department of Specialty Medicine, Appalachian Rural Health Institute, Edison Biotechnology Institute, Department of Biomedical Sciences, Biomedical Engineering Program, Interthyr Corporation, Diabetes Research Center
Search for other papers by Christopher Schwartz in
Google Scholar
PubMed
Search for other papers by Christopher J Lewis in
Google Scholar
PubMed
Department of Specialty Medicine, Appalachian Rural Health Institute, Edison Biotechnology Institute, Department of Biomedical Sciences, Biomedical Engineering Program, Interthyr Corporation, Diabetes Research Center
Department of Specialty Medicine, Appalachian Rural Health Institute, Edison Biotechnology Institute, Department of Biomedical Sciences, Biomedical Engineering Program, Interthyr Corporation, Diabetes Research Center
Department of Specialty Medicine, Appalachian Rural Health Institute, Edison Biotechnology Institute, Department of Biomedical Sciences, Biomedical Engineering Program, Interthyr Corporation, Diabetes Research Center
Search for other papers by Leonard D Kohn in
Google Scholar
PubMed
Department of Specialty Medicine, Appalachian Rural Health Institute, Edison Biotechnology Institute, Department of Biomedical Sciences, Biomedical Engineering Program, Interthyr Corporation, Diabetes Research Center
Department of Specialty Medicine, Appalachian Rural Health Institute, Edison Biotechnology Institute, Department of Biomedical Sciences, Biomedical Engineering Program, Interthyr Corporation, Diabetes Research Center
Search for other papers by Frank L Schwartz in
Google Scholar
PubMed
Visceral adipocytes and associated macrophages produce and release excessive amounts of biologically active inflammatory cytokines via the portal and systemic vascular system, which induce insulin resistance in insulin target tissues such as fat, liver, and muscle. Free fatty acids (FFAs) absorbed via the portal system or released from adipocytes also induce insulin resistance. In this report, we show that phenylmethimazole (C10) blocks basal IL6 and leptin production as well as basal Socs-3 expression in fully differentiated 3T3L1 cells (3T3L1 adipocytes) without affecting insulin-stimulated AKT signaling. In addition, C10 inhibits palmitate-induced IL6 and iNos up-regulation in both 3T3L1 adipocytes and RAW 264.7 macrophages, LPS-induced NF-κB and IFN-β activation in 3T3L1 cells, and LPS-induced iNos, Ifn- β, Il1 β, Cxcl10, and Il6 expression in RAW 264.7 macrophages. C10 also blocks palmitate-induced Socs-3 up-regulation and insulin receptor substrate-1 (IRS-1) serine 307 phosphorylation in 3T3L1 adipocytes. Additionally, we show for the first time that although palmitate increases IRS-1 serine 307 phosphorylation in 3T3L1 adipocytes, AKT serine 473 phosphorylation is enhanced, not reduced, by palmitate. These results suggest that through inhibition of FFA-mediated signaling in adipocytes and associated macrophages, as well as possibly other insulin target cells/tissues (i.e. non-immune cells), C10 might be efficacious to prevent or reverse cytokine-induced insulin resistance seen in obesity-related insulin resistance and type 2 diabetes mellitus.
Novo Nordisk Foundation Center for Basic Metabolic Research, Department of Biomedical Sciences, Wellcome Trust – MRC Institute of Metabolic Science, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3b, 2200 Copenhagen, Denmark
Search for other papers by Berit Svendsen in
Google Scholar
PubMed
Search for other papers by Ramona Pais in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Department of Biomedical Sciences, Wellcome Trust – MRC Institute of Metabolic Science, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3b, 2200 Copenhagen, Denmark
Search for other papers by Maja S Engelstoft in
Google Scholar
PubMed
Search for other papers by Nikolay B Milev in
Google Scholar
PubMed
Search for other papers by Paul Richards in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Department of Biomedical Sciences, Wellcome Trust – MRC Institute of Metabolic Science, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3b, 2200 Copenhagen, Denmark
Search for other papers by Charlotte B Christiansen in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Department of Biomedical Sciences, Wellcome Trust – MRC Institute of Metabolic Science, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3b, 2200 Copenhagen, Denmark
Search for other papers by Kristoffer L Egerod in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Department of Biomedical Sciences, Wellcome Trust – MRC Institute of Metabolic Science, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3b, 2200 Copenhagen, Denmark
Search for other papers by Signe M Jensen in
Google Scholar
PubMed
Search for other papers by Abdella M Habib in
Google Scholar
PubMed
Search for other papers by Fiona M Gribble in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Department of Biomedical Sciences, Wellcome Trust – MRC Institute of Metabolic Science, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3b, 2200 Copenhagen, Denmark
Search for other papers by Thue W Schwartz in
Google Scholar
PubMed
Search for other papers by Frank Reimann in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Department of Biomedical Sciences, Wellcome Trust – MRC Institute of Metabolic Science, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3b, 2200 Copenhagen, Denmark
Search for other papers by Jens J Holst in
Google Scholar
PubMed
The incretin hormones glucagon-like peptide-1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP) are secreted from intestinal endocrine cells, the so-called L- and K-cells. The cells are derived from a common precursor and are highly related, and co-expression of the two hormones in so-called L/K-cells has been reported. To investigate the relationship between the GLP1- and GIP-producing cells more closely, we generated a transgenic mouse model expressing a fluorescent marker in GIP-positive cells. In combination with a mouse strain with fluorescent GLP1 cells, we were able to estimate the overlap between the two cell types. Furthermore, we used primary cultured intestinal cells and isolated perfused mouse intestine to measure the secretion of GIP and GLP1 in response to different stimuli. Overlapping GLP1 and GIP cells were rare (∼5%). KCl, glucose and forskolin+IBMX increased the secretion of both GLP1 and GIP, whereas bombesin/neuromedin C only stimulated GLP1 secretion. Expression analysis showed high expression of the bombesin 2 receptor in GLP1 positive cells, but no expression in GIP-positive cells. These data indicate both expressional and functional differences between the GLP1-producing ‘L-cell’ and the GIP-producing ‘K-cell’.